
METHOCARBAMOL- methocarbamol tablet American Health Packaging

Methocarbamol Tablets USP 8455901/0320 Rx only

DESCRIPTION

Methocarbamol tablets USP a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

The chemical name of methocarbamol is 3-(2-methoxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula C $_{11}$ H $_{15}$ NO $_5$. Its molecular weight is 241.24. The structural formula is shown below.



Methocarbamol is a white powder, sparingly soluble in water and chloroform, soluble in alcohol (only with heating) and propylene glycol, and insoluble in benzene and n-hexane.

Methocarbamol tablets USP are available as 500 mg and 750 mg tablets for oral administration. Methocarbamol tablets USP 500 mg and 750 mg contain the following inactive ingredients: sodium lauryl sulfate, sodium starch glycolate, povidone K 90, polyethylene glycol, magnesium stearate, colloidal silicon dioxide, low substituted hydroxypropyl cellulose and stearic acid.

CLINICAL PHARMACOLOGY

The mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

Pharmacokinetics

In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of methocarbamol also is likely. Essentially all methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged methocarbamol also are excreted in the urine.

Special populations

Elderly

The mean (\pm SD) elimination half-life of methocarbamol in elderly healthy volunteers (mean (\pm SD) age, 69 (\pm 4) years) was slightly prolonged compared to a younger (mean (\pm SD) age, 53.3 (\pm 8.8) years), healthy population (1.5 (\pm 0.4) hours versus 1.1 (\pm 0.27) hours, respectively). The fraction of bound methocarbamol was slightly decreased in the elderly versus younger volunteers (41 to 43% versus 46 to 50%, respectively).

Renally impaired

The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, although the mean (\pm SD) elimination half-life in these two groups was similar: 1.2 (\pm 0.6) versus 1.1 (\pm 0.3) hours, respectively.

Hepatically impaired

In 8 patients with cirrhosis secondary to alcohol abuse, the mean total clearance of methocarbamol was reduced approximately 70% compared to that obtained in 8 ageand weight-matched normal subjects. The mean (\pm SD) elimination half-life in the cirrhotic patients and the normal subjects was 3.38 (\pm 1.62) hours and 1.11 (\pm 0.27) hours, respectively. The percent of methocarbamol bound to plasma proteins was decreased to approximately 40 to 45% compared to 46 to 50% in the normal subjects.

INDICATIONS & USAGE

Methocarbamol tablets USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.

CONTRAINDICATIONS

Methocarbamol tablets USP are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

WARNINGS

Since methocarbamol may possess a general CNS depressant effect, patients receiving methocarbamol tablets USP should be cautioned about combined effects with alcohol and other CNS depressants.

Safe use of methocarbamol tablets USP has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol tablets USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see PRECAUTIONS, Pregnancy).

Use In Activities Requiring Mental Alertness

Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are

reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

PRECAUTIONS

Information for Patients

Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.

Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

Drug Interactions

See WARNINGS and PRECAUTIONS for interaction with CNS drugs and alcohol.

Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.

Drug/Laboratory Test Interactions

Methocarbamol may cause a color interference in certain screening tests for 5hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.

Carcinogenesis, Mutagenesis. Impairment of Fertility

Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.

Pregnancy

Teratogenic effects -Pregnancy Category C

Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol tablets USP should be given to a pregnant woman only if clearly needed.

Safe use of methocarbamol tablets USP has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol tablets USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (**see WARNINGS**).

Nursing Mothers

Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when methocarbamol tablets USP are administered to a nursing woman.

Pediatric Use

Safety and effectiveness of methocarbamol tablets USP in pediatric patients below the age of 16 have not been established.

ADVERSE REACTIONS

Adverse reactions reported coincident with the administration of methocarbamol include:

Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headache *Cardiovascular system*: Bradycardia, flushing, hypotension, syncope, thrombophlebitis *Digestive system*: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting

Hemic and lymphatic system: Leukopenia

Immune system: Hypersensitivity reactions

Nervous system: Amnesia, confusion, diplopia, dizziness or lightheadedness,

drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo

Skin and special senses: Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticarial

OVERDOSAGE

Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma.

In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.

Treatment

Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.

DOSAGE & ADMINISTRATION

Methocarbamol Tablets USP 500 mg – Adults: Initial dosage: 3 tablets q.i.d. Maintenance dosage: 2 tablets q.i.d.

Methocarbamol Tablets USP 750 mg – Adults: Initial dosage: 2 tablets q.i.d. Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d. Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

HOW SUPPLIED

Methocarbamol tablets USP 500 mg are white to off white, capsule shaped, tablets debossed with 'H' on scored side and '114' on unscored side. They are supplied as follows:

Unit dose packages of 100 (10 x 10) NDC 60687-559-01

Methocarbamol tablets USP 750 mg are white to off white, capsule shaped, tablets debossed with 'H' on one side and '115' on other side. They are supplied as follows: Unit dose packages of 100 (10×10) NDC 60687-568-01

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

FOR YOUR PROTECTION: Do not use if blister is torn or broken.

PACKAGING INFORMATION

American Health Packaging unit dose blisters (see How Supplied section) contain drug product from Camber Pharmaceuticals, Inc. as follows: (500 mg/ 100 UD) NDC 60687-559-01 packaged from NDC 31722-533 (750 mg/ 100 UD) NDC 60687-568-01 packaged from NDC 31722-534

Distributed by: **American Health Packaging** Columbus, OH 43217

8455901/0320

Package/Label Display Panel - Carton - 500 mg

NDC 60687-**559**-01

Methocarbamol Tablets USP

500 mg

100 Tablets (10 x 10)

Rx Only



NDC 60687-**559**-01

Methocarbamol Tablets USP

500 mg

100 Tablets (10 x 10)

Rx Only

Distributed by: American Health Packaging Columbus, Ohio 43217

> 755901 0455901/0320

NDC 60687- **559**-01

Methocarbamol Tablets USP

500 mg

100 Tablets (10 x 10)

Rx Only

Each Uncoated Tablet Contains:

Methocarbamol USP500 mg

Usual Dosage: Two to four tablets four times daily. See package insert for full prescribing information.

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Keep this and all drugs out of reach of children.

FOR YOUR PROTECTION: Do not use if blister is torn or broken.

The drug product contained in this package is from NDC # 31722-533, Camber Pharmaceuticals, Inc.

Distributed by: American Health Packaging Columbus, Ohio 43217

755901 0455901/0320

Package/Label Display Panel - Blister - 500 mg

Methocarbamol Tablet USP 500 mg RCC II (CC () () () () () () () () (Expiry: xx/xx Lot: xxxxxx	Expiry: xx/xx Lot: xxxxxx	Methocarbamol Tablet USP 500 mg FCC f ESSESSESSESSES 101 F ESSESSESSESSESSESSESSESSESSESSESSESSESS
Methocarbamol Tablet USP 500 mg EV:: f :::::::::::::::::::::::::::::::	Expiry: xd/xx Lat: xxxxxx	Expiry: xx/xx Lot: xxxxxx	Methocarbamol Tablet USP 500 mg RCC / BCS / SCEI/I
Methocarbamol Tablet USP 500 mg RYC II / D'1 X I / VEB/I IIII / D'1 X I / VEB/I (01) 003 60687 559 11 7 American Hath Percagan, Columba, Chio 43217	Expiry: xx/xx Lot: xxxxxx	Expiry: xx/xx Lot: xxxxxx	Methocarbamol Tablet USP 500 mg FCC: If BCCtl SCIP (01) 003 60687 559 11 7 Areasan Heath Packaging, Columbus, Otio 4217
Methocarbamol Tablet USP 500 mg BY2: If D1 \$1 { YEB/FI III III IIII IIIIIIIIIIIIIIIIIIIIIII	Expiry: xx/xx Lot: xxxxx	Expiry: xx/xx Lot: xxxxxx	Methocarbamol Tablet USP 500 mg EV:) // E::til://////////////////////////////////
Methocarbamol Tablet USP 500 mg CC: II C:	Expiry: xx/xx Lot: xxxxxx	Expiry: xo/xx Lot: x00000	Methocarbamol Tablet USP 500 mg bV() { B(1) () () () () () () () () () () () () () () () () () () ()

Methocarbamol Tablet USP

500 mg

Package/Label Display Panel - Carton - 750 mg

NDC 60687-**568**-01

Methocarbamol Tablets USP

750 mg

100 Tablets (10 x 10)

Rx Only



NDC 60687-**568**-01

Methocarbamol Tablets USP

750 mg

100 Tablets (10 x 10)

Rx Only

American Health Packaging Columbus, Ohio 43217

> 756801 0456801/0320

NDC 60687- **568**-01

Methocarbamol Tablets USP

750 mg

100 Tablets (10 x 10)

Rx Only

Each Uncoated Tablet Contains:

Methocarbamol USP750 mg

Usual Dosage: Two tablets three times daily. See package insert for full prescribing information.

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Keep this and all drugs out of reach of children.

FOR YOUR PROTECTION: Do not use if blister is torn or broken.

The drug product contained in this package is from NDC # 31722-534, Camber Pharmaceuticals, Inc.

Distributed by: American Health Packaging Columbus, Ohio 43217

756801 0456801/0320

Package/Label Display Panel - Blister - 750 mg

Methocarbamol Tablet USP 750 mg Model 14 Diff 21 25 EM (01) 003 60687 568 11 9 Arrecan Health Packages, Columbus, Onio 43217	Expiry: xx/xx Lot: xxxxxx	Expiry: xotxx Lot: xxxxxx	Methocarbamol Tablet USP 750 mg EV:: If D'1tR'SELA (01) 003 60687 568 11 9 American Heads Packaging, Columbus, Chin 43217
Methocarbamol Tablet USP 750 mg MCC t DC t C ST T ST T (01) 003 60687 568 11 9 Arrefean Heath Packaging, Chamber, Onio 43217	Expiry: xx/xx Lot xxxxxx	Expiry: xx/xx Lot: xxxxxx	Methocarbamol Tablet USP 750 mg HVAIII DVAIIA EIIA (01) 003 60687 568 11 9 American Headh Packaging, Colonias, Chio 43217
Methocarbamol Tablet USP 750 mg Tablet I I I I I I I I I I I I I I I I I I I	Expiry: xx/xx Lot: xxxxxx	Expiry: xx/xx Lot: x00000	Methocarbamol Tablet USP 750 mg Control (Control (Contro) (Control (Contro) (Contro)
Methocarbamol Tablet USP 750 mg Tablet B: Strate BIA (01) 003 60687 568 11 9 American Health Pechaging, Columbus, Chio 43217	Expiry: xx/xx Lot: xxxxx	Expiry: xx/xx Lot: x00000	Methocarbamol Tablet USP 750 mg RCC II & RCC II S (01) 003 60697 568 11 9 American Heath Packaging, Columba, Chio 43217
Methocarbamol Tablet USP 750 mg HVA II & CARAGE III (01) 003 60687 568 11 9 American Heath Packaging, Columbia, Onio 43217	Expiry: xx/xx Lot: xxxxxx	Expiry: xx/xx Lot: xxxxxx	Methocarbamol Tablet USP 750 mg Tablet I SP 750 mg (1) 003 60687 568 11 9 (1) 003 60687 568 11 9

Methocarbamol Tablet USP

750 mg

METHOCARBAMOL methocarbamol tablet						
Product Information						
Product Type	HUMAN PRESCRIPTION DRUG	ltem Code (Source)		NDC:60687-559(533)	NDC:31722-	
Route of Administration	ORAL					
Active Ingredient/Active	Mojety					
-	•		Ba	sic of Strongt	Strongth	
Ingredient Name Basis of Strength Strength METHOCARBAMOL (UNII: 1250D7737X) (METHOCARBAMOL - UNII:1250D7737X) METHOCARBAMOL 500						
Inactive Ingredients						
Ingredient Name					Strength	
SODIUM LAURYL SULFATE (UNII:	368GB5141J)					

SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)	
POVIDONE K90 (UNII: RDH86HJV5Z)	
POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
HYDROXYPROPYL CELLULOSE (1600000 WAMW) (UNII: RFW2ET671P)	
STEARIC ACID (UNII: 4ELV7Z65AP)	

Product Characteristics

Color	white (White to Off-white)	Score	2 pieces
Shape	OVAL (Capsule shaped)	Size	15mm
Flavor		Imprint Code	114;H
Contains			

Packaging

1 NDC:60687-559- 01 100 in 1 BOX, UNIT-DOSE 03/25/2020 1 NDC:60687-559- 1 in 1 BLISTER PACK; Type 0: Not a Combination	-	Marketing Date	Marketing Start Date	Package Description	ltem Code	#
NDC:60687-559- 1 in 1 BLISTER PACK; Type 0: Not a Combination			03/25/2020	⁹⁻ 100 in 1 BOX, UNIT-DOSE	NDC:60687-559- 01	1
11 Product					NDC:60687-559- 11	1

17- 16- 1 5-			OC NUMITS N
14- 13- 12-			ALTRATS NO
11– 10–			
9- 8- 7-			C NUM OF MET
6 5 4	111	1	TRANTS MED
3- 2- 1-		1	
0 – mi		 10 11 12 13 14	 15 16
Marketing In	formation		
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date

METHOCARBAMOL methocarbamol tablet				
Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	ltem Code (Source)	NDC:60687-568(N 534)	DC:31722-
Route of Administration	ORAL			
Active Ingredient/Active	Moiety			
Ingr	edient Name		Basis of Strength	Strength
METHOCARBAMOL (UNII: 1250D7	737X) (METHOCARBAMOL - U	NII:1250D7737X)	METHOCARBAMOL	750 mg

03/25/2020

ANDA

ANDA090200

Inactive Ingre	dients		
	Ingredient Name		Strength
SODIUM LAURYL	SULFATE (UNII: 368GB5141J)		
SODIUM STARCH	GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2))	
POVIDONE K90 (U	NII: RDH86HJV5Z)		
POLYETHYLENE G	LYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)		
MAGNESIUM STEA	RATE (UNII: 70097M6I30)		
SILICON DIOXIDE	(UNII: ETJ7Z6XBU4)		
HYDROXYPROPYL	CELLULOSE (1600000 WAMW) (UNII: RFW2ET6	71P)	
STEARIC ACID (UN	II: 4ELV7Z65AP)		
Product Chara	acteristics		
Color	white (White to Off-white)	Score	no score
Shape	OVAL (Capsule shaped)	Size	19mm
Flavor		Imprint Code	115;H
Contains			
Packaging			
# Item Code	Package Description	Marketing Start Date	Marketing End Date
1 NDC:60687-568-	100 in 1 BOX, UNIT-DOSE	03/25/2020	
1 01	100 III 1 BOX, ONIT BOSE		

17— 16—				A PULLATS M
15—				
14—	U			Chille Chille
13— 12—	()		ALC: NO
12	1			0199
10—				
9—	CT TO MILLION TO	and the second	No-Multimot	
8—				Don That
7				2169
5—				1000
4-				A NE
3— 2—				APO'S
1_				
0 mm []				
0 1	23456789	10 11	12 13 14 15 16	17 18 19 20
Marketing Ir	formation			
Marketing Category	Application Number or Mon Citation	ograph	Marketing Start Date	Marketing End Date
ANDA	ANDA090200		03/25/2020	

Labeler - American Health Packaging (929561009)

Establishment			
Name	Address	ID/FEI	Business Operations
American Health Packaging		929561009	repack(60687-559, 60687-568)

Revised: 10/2022

American Health Packaging